Patrys

A novel antibody approach for fighting cancer and NETosis-driven inflammatory diseases

Patrys’ deoxymab platform is based on unique, proprietary antibodies

Target DNA processes inside cells and the cell nucleus

Cross the blood-brain barrier (BBB)

Inhibit NETosis which is involved in the development of cancer, and many infectious, inflammatory and autoimmune diseases

Patrys is using deoxymabs to develop revolutionary cancer and inflammatory disease therapies

Single agent therapies

To treat diseases causes by NETosis including certain cancers and inflammatory conditions

Combination therapies

Using deoxymabs in combination with other therapeutic treatments

Targeting agent

Delivers therapeutic payloads into the cell nucleus

Company

Please click here to view our latest company presentation.

Announcements

Invest

Please click here to find out more about investing in Patrys.

Contact

Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
Australia

ABN 97 123 055 363
Phone +61 3 9670 3273

Latest News

Menu